Literature DB >> 9359491

Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose beta1-3 N-acetyl-galactosamine).

L G Yu1, B Jansson, D G Fernig, J D Milton, J A Smith, O V Gerasimenko, M Jones, J M Rhodes.   

Abstract

In many tissues, the TF (Thomsen-Friedenreich) blood group antigen (Galbeta1-3GalNAc alpha-) behaves as an onco-foetal carbohydrate antigen, showing increased expression in malignancy and hyperplasia. Dietary lectins which bind the TF antigen have marked effects on proliferation of epithelial cells without cytotoxicity. This led us to speculate that anti-TF antibodies, including those that naturally occur in humans, might have similar effects. Five anti-TF antibodies, TF2 (human), TF5 (human), 5A8 (mouse), 8D8 (mouse) and BM22 (mouse), but not TFI (human) or 49H.9 (mouse), showed marked dose-dependent stimulation (95-192%) of [3H]thymidine incorporation by HT29 human colon cancer cells. Similar stimulation of proliferation of HT29 cells by these monoclonal antibodies (MAbs) was found when cell count assessment was used. Antibody-stimulated proliferation was inhibited by co-incubation with glycoproteins expressing Galbeta1-3GalNAc alpha- (asialo glycophorin or [Galbeta1-3GalNAc alpha-O-p-aminophenyl]n-human serum albumin). A proliferative effect of these antibodies was also demonstrated on human colon cancer cell lines LS174T and HT29-MTX but not on Caco-2 cells. Although immunoblotting showed similar binding patterns of all the antibodies on HT29 cell membrane extracts, there was little correlation between cell surface binding assessed by immunofluorescence and proliferative response, and internalization of the biotinylated antibody TF5 was demonstrated by confocal microscopy. Our results provide further evidence that cell surface glycoproteins which express TF antigen may play an important role in the regulation of cell proliferation and also suggest that human anti-TF antibodies may have proliferative effects on cells which express TF antigen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359491     DOI: 10.1002/(sici)1097-0215(19971104)73:3<424::aid-ijc18>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Structural insights into the recognition mechanism between an antitumor galectin AAL and the Thomsen-Friedenreich antigen.

Authors:  Lei Feng; Hui Sun; Ying Zhang; De-Feng Li; Da-Cheng Wang
Journal:  FASEB J       Date:  2010-06-07       Impact factor: 5.191

2.  Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody.

Authors:  Udo Jeschke; Uwe Karsten; Irmi Wiest; Sandra Schulze; Christina Kuhn; Klaus Friese; Hermann Walzel
Journal:  Histochem Cell Biol       Date:  2006-04-11       Impact factor: 4.304

3.  Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.

Authors:  Jamie Heimburg; Jun Yan; Susan Morey; Olga V Glinskii; Virginia H Huxley; Linda Wild; Robert Klick; Rene Roy; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 4.  Altered glycosylation in inflammatory bowel disease: a possible role in cancer development.

Authors:  B J Campbell; L G Yu; J M Rhodes
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

5.  Suppression of core 1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and Core 3 glycans in human colon cancer cells.

Authors:  Hannah Barrow; Benjamin Tam; Carrie A Duckworth; Jonathan M Rhodes; Lu-Gang Yu
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

6.  Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker.

Authors:  Sankaranarayanan Kannan; Reddi A Lakku; Devaraj Niranjali; Kamala Jayakumar; Arulraj H Steven; V V Taralakshmi; S Chandramohan; Ramathilakam Balakrishnan; Christian Schmidt; Devaraj Halagowder
Journal:  Mol Cancer       Date:  2003-11-05       Impact factor: 27.401

7.  Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.

Authors:  Oleg Kurtenkov; Kersti Klaamas
Journal:  Dis Markers       Date:  2015-11-18       Impact factor: 3.434

Review 8.  Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.

Authors:  Oleg Kurtenkov
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.